Skip to content

About Duchenne

/
About Duchenne

Duchenne muscular dystrophy, often referred to as DMD, or simply Duchenne, is the most common form (of more than 30 types) of muscular dystrophy.

Muscular dystrophy is an overarching term for a group of muscle diseases, defined by muscle weakness. The Canadian Neuromuscular Disease Registry (CNDR) estimates there are more than 800 boys and young men in Canada currently living with Duchenne muscular dystrophy and coping with its debilitating symptoms.

Receiving a diagnosis of Duchenne can be overwhelming, but we are here to make the journey a little easier for families who are searching for a more hopeful way forward. Our organization wants to connect you with the right tools to help you navigate your journey and ensure you know you are not alone.

We believe that when it comes to dealing with Duchenne, knowledge is not only power, but it is a source of comfort for families who are searching for answers that may change the trajectories of their sons’ lives.

Explore our site to learn more about what Duchenne is, how it affects those who have it and what your options for treatment are. If you have any questions about our web content or want to connect with other families who are on similar journeys, please do not hesitate to reach out.

Duchenne Basics

Duchenne muscular dystrophy is an extremely complex disease with a broad range of progressive symptoms. This section is intended to explain the what, why and how behind the most common form of muscular dystrophy diagnosed in children.

Diagnosis

Early diagnosis of Duchenne muscular dystrophy is the best way to enhance your child’s short and long-term outcomes. Learn more about the most common signs and symptoms and the types of testing available to support your journey to diagnosis.

Read the latest in Research and Drug Development

Pfizer has created a survey aimed at better understanding the economic burden of caregivers for a child/children diagnosed with Duchenne muscular dystrophy. Please complete the survey by Monday, August 8, 2022.
Capricor Therapeutics has begun dosing in their HOPE-3 study, a Phase 3 clinical trial investigating the cell therapy, CAP-1002, for treating late-stage Duchenne muscular dystrophy.
Edgewise Therapeutics has announced the initiation of the CANYON Phase 2 clinical trial evaluating EDG-5506 in individuals with Becker muscular dystrophy.